Cannabidiol Μay Prolong Survival in Patients With Glioblastoma Multiforme

Rudolf Likar; Markus Koestenberger; Martin Stutschnig; Gerhard Nahler

doi:10.21873/cdp.10011

Cannabidiol Μay Prolong Survival in Patients With Glioblastoma Multiforme

Rudolf Likar (First author)
, Markus Koestenberger
, Martin Stutschnig
, Gerhard Nahler

Medical University Graz

Research output: Contribution to journal › Research article

Abstract

BACKGROUND: Glioblastoma multiforme (GBM) is a relatively rare type of brain tumour with an incidence rate around 6 per 100,000. Even with the widely practiced combination of radiotherapy with adjuvant temozolomide, the median overall survival remains low with just 13.5 to 16 months after diagnosis.

PATIENTS AND METHODS: We retrospectively reviewed the survival of a cohort of 15 consecutive, unselected patients with histopathologically confirmed glioblastoma multiforme (GBM) who received CBD (400 to 600 mg orally per day) in addition to standard therapy (maximum resection of the tumour followed by radio-chemotherapy).

RESULTS: Of 15 patients, seven (46.7%) are now living for at least 24 months, and four (26.7%) for at least 36 months. This is more than twice as long as has been previously reported in the literature. The mean overall survival is currently 24.2 months (median 21 months).

CONCLUSION: CBD is a well supported co-medication and seems to prolong the survival of patients with glioblastoma multiforme.

Original language	English
Pages (from-to)	77-82
Number of pages	6
Journal	Cancer Diagnosis and Prognosis
Volume	1
Issue number	2
DOIs	https://doi.org/10.21873/cdp.10011
Publication status	Published - 3 May 2021

Branches of science

302 Clinical Medicine

DOI

10.21873/cdp.10011

Cite this

@article{29ca9a0c52db490eba5830ad9852f252,

title = "Cannabidiol Μay Prolong Survival in Patients With Glioblastoma Multiforme",

abstract = "BACKGROUND: Glioblastoma multiforme (GBM) is a relatively rare type of brain tumour with an incidence rate around 6 per 100,000. Even with the widely practiced combination of radiotherapy with adjuvant temozolomide, the median overall survival remains low with just 13.5 to 16 months after diagnosis.PATIENTS AND METHODS: We retrospectively reviewed the survival of a cohort of 15 consecutive, unselected patients with histopathologically confirmed glioblastoma multiforme (GBM) who received CBD (400 to 600 mg orally per day) in addition to standard therapy (maximum resection of the tumour followed by radio-chemotherapy).RESULTS: Of 15 patients, seven (46.7\%) are now living for at least 24 months, and four (26.7\%) for at least 36 months. This is more than twice as long as has been previously reported in the literature. The mean overall survival is currently 24.2 months (median 21 months).CONCLUSION: CBD is a well supported co-medication and seems to prolong the survival of patients with glioblastoma multiforme.",

author = "Rudolf Likar and Markus Koestenberger and Martin Stutschnig and Gerhard Nahler",

year = "2021",

month = may,

day = "3",

doi = "10.21873/cdp.10011",

language = "English",

volume = "1",

pages = "77--82",

journal = "Cancer Diagnosis and Prognosis",

issn = "2732-7787",

publisher = "International Institute of Anticancer Research",

number = "2",

}

TY - JOUR

T1 - Cannabidiol Μay Prolong Survival in Patients With Glioblastoma Multiforme

AU - Koestenberger, Markus

AU - Stutschnig, Martin

AU - Nahler, Gerhard

A2 - Likar, Rudolf

PY - 2021/5/3

Y1 - 2021/5/3

N2 - BACKGROUND: Glioblastoma multiforme (GBM) is a relatively rare type of brain tumour with an incidence rate around 6 per 100,000. Even with the widely practiced combination of radiotherapy with adjuvant temozolomide, the median overall survival remains low with just 13.5 to 16 months after diagnosis.PATIENTS AND METHODS: We retrospectively reviewed the survival of a cohort of 15 consecutive, unselected patients with histopathologically confirmed glioblastoma multiforme (GBM) who received CBD (400 to 600 mg orally per day) in addition to standard therapy (maximum resection of the tumour followed by radio-chemotherapy).RESULTS: Of 15 patients, seven (46.7%) are now living for at least 24 months, and four (26.7%) for at least 36 months. This is more than twice as long as has been previously reported in the literature. The mean overall survival is currently 24.2 months (median 21 months).CONCLUSION: CBD is a well supported co-medication and seems to prolong the survival of patients with glioblastoma multiforme.

AB - BACKGROUND: Glioblastoma multiforme (GBM) is a relatively rare type of brain tumour with an incidence rate around 6 per 100,000. Even with the widely practiced combination of radiotherapy with adjuvant temozolomide, the median overall survival remains low with just 13.5 to 16 months after diagnosis.PATIENTS AND METHODS: We retrospectively reviewed the survival of a cohort of 15 consecutive, unselected patients with histopathologically confirmed glioblastoma multiforme (GBM) who received CBD (400 to 600 mg orally per day) in addition to standard therapy (maximum resection of the tumour followed by radio-chemotherapy).RESULTS: Of 15 patients, seven (46.7%) are now living for at least 24 months, and four (26.7%) for at least 36 months. This is more than twice as long as has been previously reported in the literature. The mean overall survival is currently 24.2 months (median 21 months).CONCLUSION: CBD is a well supported co-medication and seems to prolong the survival of patients with glioblastoma multiforme.

U2 - 10.21873/cdp.10011

DO - 10.21873/cdp.10011

M3 - Research article

C2 - 35403130

SN - 2732-7787

VL - 1

SP - 77

EP - 82

JO - Cancer Diagnosis and Prognosis

JF - Cancer Diagnosis and Prognosis

IS - 2

ER -

Cannabidiol Μay Prolong Survival in Patients With Glioblastoma Multiforme

Abstract

Branches of science

DOI

Fingerprint

Cite this